Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity
(MedPage Today) -- CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.
In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the...
In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the...